A Role for PPARβ/δ in Tumor Stroma and Tumorigenesis by Müller, Rolf et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2008, Article ID 534294, 5 pages
doi:10.1155/2008/534294
ReviewArticle
A Role for PPARβ/δ in Tumor Stroma and Tumorigenesis
Rolf M¨ uller,1 Martin K¨ omhoff,2 Jeffrey M. Peters,3 and Sabine M¨ uller-Br¨ usselbach1
1Institute of Molecular Biology and Tumor Research (IMT), Philipps-University, Emil-Mannkopﬀ-Strasse 2, 35032 Marburg, Germany
2Department of Pediatrics, Philipps-University, Baldingerstrasse, 35043 Marburg, Germany
3Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis,
312 Life Sciences Building, The Pennsylvania State University, University Park, PA 16802-1504, USA
Correspondence should be addressed to Rolf M¨ uller, rmueller@imt.uni-marburg.de
Received 28 February 2008; Accepted 1 May 2008
Recommended by Dipak Panigrahy
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a transcription factor that is activated by endogenous fatty acid
ligands and by synthetic agonists. Its role in the regulation of skeletal muscle fatty acid catabolism, glucose homeostasis, and
cellular diﬀerentiation has been established in multiple studies. On the contrary, a role for PPARβ/δ in tumorigenesis is less clear
because there are contradictory reports in the literature. However, the majority of these studies have not examined the role of
PPARβ/δ in the tumor stroma. Recent evidence suggests that stromal PPARβ/δ regulates tumor endothelial cell proliferation and
promotes diﬀerentiation leading to theproperlyorchestrated events required fortumorblood vessel formation. Thisreview brieﬂy
summarizes the signiﬁcance of these studies that may provide clues to help explain the reported discrepancies in the literature
regarding the role of PPARβ/δ in tumorigenesis.
Copyright © 2008 Rolf M¨ uller et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)
is a transcription factor that is activated by lipid-derived
ligands [1, 2]. Major functions of PPARβ/δ are associated
with the regulation of intermediary metabolism, in partic-
ular energy homeostasis, skeletal muscle lipid catabolism,
and glucose metabolism [3]. PPARβ/δ is also important
in the control of inﬂammatory responses as it modulates
the function, proliferation, diﬀerentiation, and survival
of immune cells, notably macrophages and lymphocytes
[4]. PPARβ/δ therefore represents a highly relevant drug
target for the treatment of major human diseases such as
obesity, metabolic syndrome, inﬂammatory diseases, and
arteriosclerosis, which has led to the development of several
synthetic drug agonists displaying subtype selectivity and
high-aﬃnity binding [5].
Mice lacking PPARβ/δ exhibit embryonic lethality due
to aberrant development and malfunction of the placenta,
which is, however, modulated by the genetic background [6–
8]. In line with these ﬁndings, diﬀerentiation and metabolic
function of trophoblast giant cells in vitro are dependent on
PPARβ/δ [8]. Pparb null mice also exhibit a defect in wound
healing [9], and consistent with this observation, PPARβ/δ
is critical for the AKT-mediated survival of keratinocytes
during wound healing in skin [10]. However, in contrast to
this prosurvival pathway observed in skin wound healing,
PPARβ/δ also stimulates keratinocyte terminal diﬀerentia-
tion and inhibits proliferation [6, 11–14], concomitant with
a downregulation of protein kinase C and MAP kinase
signaling [15]. Diﬀerentiation of the digestive tract is also
regulated by PPARβ/δ, where it promotes the diﬀerentiation
of Paneth cells in the intestinal crypts by downregulating the
hedgehog signaling pathway [16].
2. PPARβ/δ AND TUMORIGENESIS
Consistent with its functional role in diﬀerentiation and
proliferation, PPARβ/δ inhibits chemically induced skin
carcinogenesis as enhanced skin cancer is observed in mice
where PPARβ/δ has been deleted globally in all cells [17].
Sincenodiﬀerenceinchemicallyinducedskincarcinogenesis
is observed in mice when PPARβ/δ is deleted speciﬁcally
in basal keratinocytes [18], this suggests that the protective
eﬀect of PPARβ/δ in skin cancer may require functional
roles in other cell types found in skin. Enhanced tumor2 PPAR Research
formation has also been observed in a mouse model of Raf
oncogene-induced lung adenoma formation, but the precise
mechanisms and cell types involved are not known [19].
In the Apc/Min mouse lacking functional APC protein as
well as in azoxymethane-induced intestinal carcinogenesis,
eﬀects of PPARβ/δ have been described for tumor growth
withdiﬀerent outcomes. For example, one study reports that
PPARβ/δ isdispensibleforintestinaltumorigenesis[7],while
other studies suggest that PPARβ/δ attenuates colon cancer
by regulating colonocyte terminal diﬀerentiation [20–24].
Yet others suggest that PPARβ/δ potentiates colon cancer
by promoting cell survival pathways [25–27]. The reason
for these discrepancies, and thus the precise function of
PPARβ/δ in intestinal tumorcells,remains unclearat present
[28]. Importantly, none of these studies addressed the issue
as to whether PPARβ/δ might play a role in cells of the
tumor stoma, that is host cells recruited by the tumor, such
as endothelial cells (ECs), ﬁbroblasts and macrophages [29],
and would thus add another level of complexity regarding
the interpretation of results obtained with transgenic tumor
mouse models. Indeed, recent work suggests that PPARβ/δ
also has an essential function in the tumor stroma [30, 31],
which is discussed in the following section.
3. A ROLE FOR PPARβ/δ IN TUMOR
VASCULARIZATION
Two recent studies showed that the growth of syngeneic
tumors is impaired in mice lacking PPARβ/δ.T h i sw a s
seen with two diﬀerent subcutaneous tumor models, the
Lewis lung carcinoma (LLC1) and the B16F1 melanoma
[30, 31]. Tumor growth was initially indistinguishable in
Pparb
+/+ andPparb
−/− mice,buthaltedafterapproximately
2 weeks selectively in the Pparb
−/− mice (Figure 1), while
the inoculated Pparb
+/+ mice invariably succumbed to their
tumors within 2-3 weeks, the Pparb
−/− mice exhibited
as u r v i v a lr a t eo f>90% after six months. Histological
analyses showed that density of functional microvessels is
diminished in LLC1 tumors in Pparb
−/− mice [30, 31].
In contrast to tumors examined in Pparb
+/+ mice, the
majority of tumor microvessels in Pparb
−/− mice exhibited
a hyperplastic appearance typiﬁed by a thickened endothelial
lining and the lack of a lumen (Figure 2(a)). Consistent
with this ﬁnding, kinetic DCE-MRI analysis showed an
obstructedtumorbloodﬂowinthetumorsdevelopinginthe
Pparb
−/− mice [31]. These alterations were associated with
a striking increase in tumor endothelial cell proliferation
in the absence of PPARβ/δ expression (Figure 2(b)), and
concomitant with this hyperproliferation, the immature
ECs were surrounded by perivascular cells expressing vast
amountsofthemyoﬁbroblastmarkerα-smoothmuscleactin
(Figure 2(c)), a picture that is characteristic of endothelial
hyperplasia. These observations strongly suggest that an
abnormal organization caused by a hyperplastic response,
rather than a lack of ECs, underlies the abundance of
abnormal microvessels in Pparb
−/− mice. This is consistent
with a large body of evidence demonstrating that PPARβ/δ
can inhibit cell proliferation in a number of diﬀerent cell
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Figure 1: Growth of subcutaneous Lewis lung carcinoma (LLC1)
in syngeneic Pparb
+/+ and Pparb
−/− mice. Tumor sizes were deter-
mined at the times indicated with a caliper. The calculated volumes
are shown as mean ±SD [31]. ∗All tumor volumes <1000mm3.
types [13, 24]. Importantly, PPARβ/δ-dependent tumor
vascularization was not restricted to ectopic tumor models,
but was also seen with intestinal adenomas in APC+/min
mice which showed disorganized microvessels speciﬁcally
in a Pparb
−/− background (Figure 3). Collectively, these
observations point to a general role for PPARβ/δ in the
formation or maintenance of tumor blood vessels.
Although a defect in angiogenesis has not been observed
during normal development of Pparb
−/− mice [6–9], the
ﬁndings discussed above are consistent with previous ﬁnd-
ings pointing to a role for PPARβ/δ in terminal diﬀerenti-
ation and the control of cell proliferation in diﬀerent cell
types, including keratinocytes [12, 14, 32, 33], trophoblast
giant cells [8], and intestinal epithelial cells [16, 22]. This
suggests that PPARβ/δ is speciﬁcally required by tumor
ECs to orchestrate their proliferation and diﬀerentiation
in an environment providing an abnormally rich source
of growth factors and cytokines. A role for PPARβ/δ in
tumor vascularization is also supported by several pieces
of circumstantial evidence: Pparb is the predominant Ppar
subtype expressed in mouse and human tumor endothelial
cells, and it is upregulated by angiogenic growth factors of
the tumor microenvironment [30, 31].
4. PPARβ/δ TARGET GENES RELEVANT FOR
STROMA CELL FUNCTION
Microarray and qPCR analysis led to the identiﬁcation of
a set of genes that are diﬀerentially expressed in an in
vivo model of growth factor-induced angiogenesis (matrigel
plugs) from Pparb
+/+ and Pparb
−/− mice [31]. Consistent
with the observed hyperproliferative phenotype in Pparb
−/−
mice, three of these genes have known inhibitory functionsRolf M¨ uller et al. 3
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Figure 2: (a) Aquaporin-1immunostaining of endothelial cells and
blood vessels in subcutaneous Lewis lung carcinoma (LLC1) 14
days after inoculation into Pparb
+/+ and Pparb
−/− mice (brown
stain). Areas of tumor cell necrosis are obvious in the vicinity
of the aberrant vascular structures in Pparb
−/− mice. (b) PCNA
(proliferating cell nuclear antigen) staining of an LLC1 tumor
sectionfromaPparb
−/− mouse.Theredstainshowsahighfraction
of proliferating endothelial cells lining the tumor microvascular
structures (denoted by asterisks; 38.7% in Pparb
−/− mice versus
16.6% in Pparb
+/+ mice) [31]. (c) Aquaporin-1/α-smooth muscle
actin double immunoﬂuorescence of LLC1 tumors from Pparb
−/−
mice, showing hallmarks of a hyperplastic stroma. Red: aquaporin-
1, green: α-smooth muscle actin.
in angiogenesis (Cd36, Thbs2) or cell cycle control (Cdkn1c)
[34, 35]. Thrombospondins attenuate EC proliferation and
migrationin vitro and inhibit angiogenesis in vivo, which
is strictly dependent on their interaction with the CD36
receptor. In PPARb
−/− cells, both ligand (Thbs2) and
receptor(Cd36) genes are downregulated, suggesting that
an autocrine or paracrine signaling loop with an essential
function in modulating angiogenesis is impaired in these
cells. Very little is known about the intracellular events that
occur after binding of thrombospondin to CD36, so it is
diﬃcult to speculate at present about the CD36-triggered
signal transduction pathway(s) that is/are aﬀected in ECs
lacking PPARβ/δ expression. The third gene identiﬁed as a
PPARβ/δ target gene in this context is Cdkn1c [31], which
codes for the CIP/KIP family member p57KIP2 t h a ti ti s
likely to function as a cyclin-dependent kinase inhibitor
[34]. Thus, p57KIP2 would have a similar eﬀect on EC
Null
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Figure 3: Analysis of microvessels in intestinal adenomas from
APC
+/min mice in a PPARb
+/+ or PPARb
−/− background (31 ±
3 weeks old mice) by aquaporin-1 immunostaining of paraﬃn
sections (brown). Arrows point to normal microvessels in tumors
from PPARb
+/+ mice, lacking in PPARb
−/− mice. Highly aberrant
vascularstructureslackingalumenareseenspeciﬁcallyinPparb
−/−
mice.
proliferation as CD36 and thrombospondin, suggesting that
these molecules may act in concert. It is likely that additional
genes with functions in growth control and diﬀerentiation
will be identiﬁed as potential PPARβ/δ target genes in the
same experimental system, and it is likely that multiple
PPARβ/δ regulated genes are important in the context of
tumor stroma development and tumor angiogenesis.
5. CONCLUSIONS
The ﬁndings discussed above are consistent with a model
where PPARβ/δ is required to modulate the angiogenic
response to growth factors during the ﬁnal stages of tumor
angiogenesis, which is characterized by an inhibition of EC
proliferation and the acquisition of a fully diﬀerentiated
phenotype [36]. The lack of PPARβ/δ with the ensuing
decreased expression of negative regulators of proliferation
may result in a deregulation of angiogenesis with the
consequence of tumor endothelial hyperplasia. A similar
phenotype of enhanced, but nonproductive, angiogenesis
has very recently been described in mice lacking the Notch
ligand Delta-Like 4 (Dll4) [37, 38]. In contrast to PPARβ/δ,
however,Dll4isessentialnotonlyfortumorangiogenesisbut
also for embryonic vascular development and arteriogenesis
[39], and there seems to be no cross-talk or interaction
between both the PPARβ/δ and Notch/Dll4 pathways. This
suggeststhatmultipleandpresumablymutuallyindependent
regulatory mechanisms are required to prevent the dereg-
ulation of tumor EC proliferation and the occurrence of
nonproductive angiogenesis. The current evidence suggests
that PPARβ/δ is such a regulator.
Previous studies addressing the role of PPARβ/δ in
tumorigenesis have yielded partly conﬂicting results leav-
ing it unclear whether PPARβ/δ has tumor-promoting or
suppressing properties, in particular in colon cancer models
(reviewed in [28]). Our ﬁndings provide some insight that
may eventually help to resolve this issue. PPARβ/δ may
have diﬀerent functions in tumor stroma and in certain4 PPAR Research
tumor cells with opposing eﬀects on tumor growth. Clearly,
a detailed understanding of these complexities will be a
prerequisite for the development of PPARβ/δ directed drugs
and their clinical application.
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